{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:36:11Z","timestamp":1787067371170,"version":"build-2736575974"},"reference-count":51,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>Background: Ambulatory individuals with spinal muscular atrophy experience weakness and impairments of speed and endurance. This leads to decreased motor skill performance required for daily living including transitioning from floor to stand, climbing stairs, and traversing short and community distances. Motor function improvements have been reported in individuals receiving nusinersen, but changes in timed functional tests (TFTs) which assess shorter distance walking and transitions have not been well documented. Objective: To evaluate changes in TFT performance over the course of nusinersen treatment in ambulatory individuals with SMA and identify potential factors [age, SMN2 copy number, BMI, Hammersmith Functional Motor Scale Expanded (HFMSE score), Peroneal Compound Motor Action Potential (CMAP) amplitude] associated with TFT performance. Methods: Nineteen ambulatory participants receiving nusinersen were followed from 2017 through 2019 (range: 0\u2013900 days, mean 624.7 days, median 780 days); thirteen of 19 (mean age\u200a=\u200a11.5 years) completed TFTs. The 10-meter walk\/run test, time-to-rise from supine, time-to-rise from sitting, 4-stair climb, 6-minute walk test (6MWT), Hammersmith Expanded and peroneal CMAP were assessed at each visit. Linear mixed-effects models were used to evaluate unadjusted and adjusted changes in these outcomes over time. Results: Apart from time to rise from sitting and from supine, all TFTs were found to improve over the course of treatment after adjusting for baseline age and BMI. Conclusions: Improvement in TFTs over time in patients with SMA treated with nusinersen suggests that shorter TFTs may have value to assess individuals with SMA who have or later gain ambulatory function during treatment.<\/jats:p>","DOI":"10.3233\/jnd-221519","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T10:50:35Z","timestamp":1677840635000},"page":"337-348","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen"],"prefix":"10.1177","volume":"10","author":[{"given":"Kristin J.","family":"Krosschell","sequence":"first","affiliation":[{"name":"Department of Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, USA"},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurey","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Services, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"},{"name":"Division of Neurology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Services, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"},{"name":"Division of Neurology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn B.","family":"Zumpf","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA- sponsor"},{"name":"Statistical Consulting, OSF Healthcare, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Munson","sequence":"additional","affiliation":[{"name":"Chicago College of Osteopathic Medicine, Midwestern University Downers Grove, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessa","family":"Bidwell","sequence":"additional","affiliation":[{"name":"Graduate Program of Genetic Engineering, Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan P.","family":"Schulte","sequence":"additional","affiliation":[{"name":"Division of Neurology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail N.","family":"Schwaede","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA"},{"name":"Division of Neurology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber N.","family":"Buehner","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical, Inc, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"DiDonato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA"},{"name":"Stanley Manne Children\u2019s Research Institute, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Kuntz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA"},{"name":"Division of Neurology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshi K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA"},{"name":"Division of Neurology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"},{"name":"Stanley Manne Children\u2019s Research Institute, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/JND-221519_ref1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"3","key":"10.3233\/JND-221519_ref2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"issue":"11","key":"10.3233\/JND-221519_ref3","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.3233\/JND-221519_ref4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.3233\/JND-221519_ref5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.3233\/JND-221519_ref6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"issue":"2","key":"10.3233\/JND-221519_ref7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.3233\/JND-221519_ref8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"10.3233\/JND-221519_ref9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.3233\/JND-221519_ref10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.3233\/JND-221519_ref11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.3233\/JND-221519_ref12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"21","key":"10.3233\/JND-221519_ref13","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.3233\/JND-221519_ref14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.3233\/JND-221519_ref15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.3233\/JND-221519_ref16","doi-asserted-by":"crossref","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: Age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.3233\/JND-221519_ref17","doi-asserted-by":"crossref","first-page":"e0201004","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.3233\/JND-221519_ref18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.nmd.2013.06.001","article-title":"Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study","volume":"23","author":"Mazzone","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.3233\/JND-221519_ref19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JND-180327","article-title":"Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study","volume":"5","author":"Krosschell","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.3233\/JND-221519_ref20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JND-180301","article-title":"Evaluator Training and Reliability for SMA Global Nusinersen Trials1","volume":"5","author":"Glanzman","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.3233\/JND-221519_ref21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.3233\/JND-221519_ref22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mus.20018","article-title":"Motor function-muscle strength relationship in spinal muscular atrophy","volume":"29","author":"Merlini","year":"2004","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.3233\/JND-221519_ref23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: Results of a multicenter, randomized Italian study","volume":"18","author":"Merlini","year":"2003","journal-title":"J Child Neurol"},{"issue":"3","key":"10.3233\/JND-221519_ref24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01241398-200305000-00006","article-title":"Walking speed in children and young adults with neuromuscular disease: Comparison between two assessment methods","volume":"23","author":"Pirpiris","year":"2003","journal-title":"J Pediatr Ortho"},{"issue":"10","key":"10.3233\/JND-221519_ref25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"issue":"246","key":"10.3233\/JND-221519_ref26","first-page":"1","article-title":"CDC Growth Charts for the United States: Methods and development","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"issue":"1","key":"10.3233\/JND-221519_ref27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"Guidelines for the six-minute walk test","volume":"166","author":"ATS statement","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.3233\/JND-221519_ref28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JND-221519_ref29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/mus.25484","article-title":"Gait assessment with solesound instrumented footwear in spinal muscular atrophy","volume":"56","author":"Montes","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-221519_ref30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/mus.23656","article-title":"Falls and spinal muscular atrophy: Exploring cause and prevention","volume":"47","author":"Montes","year":"2013","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.3233\/JND-221519_ref31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-221519_ref32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005768-200201000-00021","article-title":"Children\u2019s OMNI scale of perceived exertion: Walking\/running evaluation","volume":"34","author":"Utter","year":"2002","journal-title":"Med Sci Sports Exerc"},{"issue":"5 Pt 1","key":"10.3233\/JND-221519_ref33","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.3233\/JND-221519_ref34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"Journal of Child Neurology"},{"issue":"9-10","key":"10.3233\/JND-221519_ref35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O\u2019Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.3233\/JND-221519_ref36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JND-221519_ref37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","article-title":"Gain and loss of abilities in type II SMA: A 12-month natural history study","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.3233\/JND-221519_ref38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nmd.2021.08.010","article-title":"Natural history of 10-meter walk\/run test performance in spinal muscular atrophy: A longitudinal analysis","volume":"32","author":"Krosschell","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.3233\/JND-221519_ref39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mus.26161","article-title":"Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history","volume":"58","author":"Arora","year":"2018","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.3233\/JND-221519_ref40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/mus.26334","article-title":"Timed function tests have withstood the test of time as clinically meaningful and responsive endpoints in duchenne muscular dystrophy","volume":"58","author":"McDonald","year":"2018","journal-title":"Muscle Nerve"},{"issue":"10063","key":"10.3233\/JND-221519_ref41","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.3233\/JND-221519_ref42","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"8","key":"10.3233\/JND-221519_ref43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nmd.2019.06.597","article-title":"Normative data and percentile curves for the three-minute walk test and timed function tests in healthy Caucasian boys from 2.5 up to 6 years old","volume":"29","author":"Hoskens","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.3233\/JND-221519_ref44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/archdischild-2014-307396","article-title":"Timed motor function tests capacity in healthy children","volume":"101","author":"Pereira","year":"2016","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.3233\/JND-221519_ref45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","author":"McGraw","year":"2017","journal-title":"BMC Neurol"},{"issue":"4","key":"10.3233\/JND-221519_ref46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.gaitpost.2004.04.006","article-title":"A comparison of gait in spinal muscular atrophy, type II and Duchenne muscular dystrophy","volume":"21","author":"Armand","year":"2005","journal-title":"Gait Posture"},{"issue":"4","key":"10.3233\/JND-221519_ref47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.3233\/JND-221519_ref48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.3233\/JND-221519_ref49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.3233\/JND-221519_ref50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.3233\/JND-221519_ref51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-221519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:22Z","timestamp":1777506742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-221519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":51,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jnd-221519","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}